GSK plc Sponsored ADR (GSK)
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK has earnings estimate cut, slow shingles vaccine uptake cited
UBS has cut its earnings per share (EPS) estimate for GSK PLC (LSE:GSK, NYSE:GSK) by 5% for fiscal years 2024 and 2025. The decision comes ahead of GSK's third-quarter results, expected on 30 October, and is mainly driven by weaker vaccine sales in the US for its key products, Shingrix and Arexvy.
GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review
The FDA accepts and grants priority review to GSK's NDA for gepotidacin for treating uncomplicated urinary tract infections. A decision is due on March 26, 2025.
3 Vaccine Stocks to Watch as Flu Season Approaches
Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring.
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.
GSK hails phase III nasal polyps success
GSK PLC (LSE:GSK, NYSE:GSK) has shared promising results from two major clinical trials (ANCHOR-1 and ANCHOR-2) testing its new treatment, depemokimab, for people suffering from chronic rhinosinusitis with nasal polyps (CRSwNP). This condition causes painful inflammation and growths in the nasal passages, leading to breathing difficulties and other uncomfortable symptoms.
GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy
New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV seasons in adults aged 60 years and above.
GSK: The Worst Is Finally Over (Rating Upgrade)
GSK's share price surged 6% yesterday in the biggest rise seen since December 2022, after the company settled 93% of cases related to the Zantac litigation. The settlement will be reflected in Q3 2024 results, with a GBP 1.8 billion charge expected to impact the earnings per share by GBP 0.44. Despite the significant charge, GSK's forward non-GAAP P/E remains reasonable at 12.4x compared to peers and the 2025 figure looks even better.
GSK Zantac settlement a 'clear win', say brokers
GSK PLC (LSE:GSK, NYSE:GSK) US$2.2 billion settlement for 93% of Zantac litigation cases is almost a best-case scenario short of no payment, according to US broker Jefferies. The broker had pencilled liability costs of between US$2-3.5 billion for the liability, adding the deal is at the bottom of its expectations.
GSK Stock Jumps as UK Drug Giant Resolves Most US Zantac Lawsuits
GSK (GSK) shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced around claims that its discontinued heartburn medicine Zantac causes cancer.
GSK jumps 6% after $2.2B Zantac settlement: why analysts see more upside
GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 billion (€2.01bn) to resolve tens of thousands of lawsuits in the US related to its discontinued heartburn medication, Zantac. The lawsuits alleged that the drug, which was pulled from the market, caused cancer.
